Pointing the way forward

CD3 T cell engagers have come a long way over the last decade.

One signal may not be enough though since the immune system has a trick most developers are overlooking.

What’s more, it has absolutely nothing to do with CD28 or 4-1BB, or even having dual antigen targets built in…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers